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ABSTRACT 
Background: Homocysteine is suspected to increase the risk of diabetes mellitus (DM) 
complications and is associated with CV disease. While dyslipidemia and DM are risk factors 
for death due to CV disease, studies on relationship between homocysteine and glycemic control 
were inconsistent. Objective: To analyze the difference of Hcy level and lipid profile on non-
DM (Group I), DM with CV (II) and without CV (III). Methods: This crosssectional study was 
conducted in Dr. Kariadi Hospital Semarang from April to October 2016. Samples were 
recruited consecutively, of which group I consists of 26 persons, group II (30) and III (30). All 
of the samples aged 30-75 years old, with long DM duration of more than 5 years. Fasting and 
2 hours PP blood glucose, lipid profile was analyzed with auto analyzer, while Hcy was analyzed 
with ELISA. Data were analyzed using independent t test. Significance is expressed at p <0.05. 
Results: A significant difference on Hcy level was found between group I and III (p=0.000), but 
not between group I and II or II and III. No significant difference was observed on total 
cholesterol (TC) and LDLC in all groups. Significant differences were found on HDLC level 
between group I and II (p=0.009); II and III (p=0.000); I and III (p=0.033). Triglyceride level on 
group I was significantly different compared to group II and III (p=0.030 and 0.013 
respectively), but was not significantly different compared to group II and III. Conclusion: 
The highest Hcy level, the lowest HDL-C and the highest triglyceride level were found in DM 
patients with cardiovascular complication. 
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WHO estimated that the number of DM 
patients in worldwide scale will increase to as 
much as 194 million people in the year 2003, and 
about two-thirds of these people lived in 
developing countries.(1)(2)  14,16 DM will have an 
impact on the quality of human resources and a 
substantial increase in health costs.(3)  
DM individuals are two to four times more 
likely to develop vascular disease than non-DM. 
Homocysteine (Hcy) is an interesting topic on 
arteriosclerosis and cardiovascular disease in 
recent years.(4) Homocysteine is an amino acid 
(AA) with AA derivatives of essential sulfhydryl 
group of methionine and source of animal 
protein.(5) Hyperhomocysteinemia/HHcy is 
predicted to increase the risk of DM complications 
and is often associated with retinopathy, 
nephropathy and cardiovascular disease (CV).(6) 
Hypotheses on rising levels of Hcy is due to 
the acceleration of glucose as a trigger of oxidative 
stress on endothelial cells have been proven in 
animal study, it is evidenced that Hcy is a more 
real trigger of endothelial dysfunction in diabetes 
than in non-DM.(5) The mechanism on how Hcy 
can increase the risk of vascular disease is not 
clear yet. In one of the studies, it is mentioned 
that HHcy stimulates the growth of vascular 
smooth muscle cells, causing intimal thickening 
of the artery walls, inhibiting oxygenation of the 
vascular wall and increasing oxygen-free radicals 
with tissue damage. Reduction of 2 O2 molecules 
on Hcy oxidation will produce free radicals and 
hydrogen peroxide and cause endothelial cell 
damage. Hyperhomocysteinemia may increase 
oxidative stress and, alongside with other 
mechanisms, induce vascular endothelial 
dysfunction and vascular smooth muscle cell 
proliferation, atherogenesis then occurs and 
increases the risk of vascular thromboembolic 
disease. (4)  
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Dyslipidemia is a risk factor of death due to 
CV disease, this risk will increase in patients with 
type 2 DM (DMT2). Hyperglycemia, diabetic 
dyslipidemia, insulin resistance and 
hypertension will produce atherogenic 
environment in circulation. However, 
atherosclerosis also occur  in patients without CV 
dyslipidemia risk factors, smoking, diabetes or 
hypertension, and this led us to think towards the 
other risk factors such as Hcy. Low HDL-
Cholesterol (HDL-C) levels in DMT2 indicate an 
inverse relationship between HDL-C and the 
incidence of cardiac abnormalities. Increased 
level of LDL-C has been known as an independent 
risk factor. The increase in LDL-C spur increased 
oxidized LDL which plays a role in heart vascular. 
Atherogenic. Hyperglycemia in DMT2 increases 
the risk of coronary arterial disease (CAD) 
incident. Increased levels of triglycerides will 
cause an increase in VLDL-C and LDL-C 
independently, and causes atherogenity LDL-C 
through triglycerides oxidized lipoproteins. The 
ratio of total cholesterol/HDL-C was higher in 
DMT2 and is stronger predictor of CAD than total 
cholesterol or HDL-C in single.(7) Recent studies 
have examined Hcy as a cardiovascular risk 
factor in DM patients, but the results of research 
on the association of Hcy levels with glycemic 
control are still inconsistent and require further 
investigation.(8) 
The purpose of this study is to analyze 
differences in homocysteine levels and lipid 
profiles in non-DM individuals, as well as DM 
patients, with and without cardiovascular 
complications 
 
MATERIALS AND METHODS 
The research was conducted after obtaining 
research permission from Health Research Ethics 
Commission Faculty of Medicine UNDIP/ Dr 
Kariadi Hospital Semarang. Before the study was 
conducted, all subjects were requested written 
informed consent. 
This is a descriptive analytic study with cross 
sectional approach. It was conducted in Dr. 
Kariadi Hospital Semarang, from April to 
October 2016. The subjects for DM patients with 
and without CV complication were taken  in DM  
and Cardiology clinic (30 patients each)  and  for 
non-DM subject were students of Faculty of 
Medicine (26 respondents). The inclusion criteria 
were age 30-75 years old, not DM (for the non-DM 
group), suffering DM > 5 years (for DM group 
without CV complication), or already suffering 
from DM over 5 years and had complications CHD 
based on minimal electrocardiography (ECG) 
examination (for DM group with cardiovascular 
complications), not taking any medications for 
lowering lipids, and willing to take part in this 
study. Patients with acute myocardial infarction 
were rejected to participate in this study. Blood 
were taken from cubital vein (5 ml) and analyzed 
for fasting and 2 hours PP glucose levels using 
auto analyzer methods. Serum Hcy levels were 
analyzed using ELISA were analyzed using SPSS 
version 21.0. Each numerical variable was tested 
for normality, on which abnormal data were 
transformed to search for a normal distribution, 
and parametric test was done by using 
independent t test. Significance is expressed at 
p<0.05. 
RESULTS 
Description of result 
The subjects of this study consisted of non-
DM individual groups: 26 persons, consisting of 
12 men (46.2%) and 14 women (53.8%). DM 
subjects without CV complications were 30 
persons, consisting of 10 men (33.3%) and 20 
women (66.7%) and DM subjects with CV were 30 
persons, consisting of 23 men (76,7%) and women 
7 people (23.3%) as can be seen in table 1. 
The mean age of non-DM group is 32.7 ± 6.3 
years, DM without CV complication 56.2 ± 9.7 
years and DM group with CV is 59.3 ± 7.8 years. 
Subject smokers were more common in the DM 
group with complications of CV counted 19 people 
(63.3%). Mean body mass index DM group with 
CV was higher than the other group that is 25.6 ± 
2.2 µml/dl. The mean duration of DM was longer 
in the DM group with CV complications (9.0 ± 3.5 
years) than in the DM without CV (6.9 ± 3.2 
years). Mean fasting blood glucose level of non-
DM group was 84.1 ± 9.1 mg/dl, DM group 
without CV was 167.7 ± 52.4 mg/dl and DM with 
CV complication was 186.9 ± 90.0 mg/dl. 
However, the mean of 2 hours PP glucose levels of 
both DM groups with and without CV 
complications were similar. (See table 1). 
The mean Hcy levels were the lowest in 
control group (7.7 ± 1.7 mg / dl). Groups of DM 
with and without CV complications were similar, 
13.1 ± 3.7 vs. 13.1 ± 15.7 mg / dl, respectively. 
The mean of total cholesterol levels of the 
non-DM and DM groups with no similar CV 
complications were (183.2 ± 32.2 mg / dl and 183.2 
± 34.9 mg / dl). DM group with lower CV 
complications (165.0 ± 50.5 mg / dl). The highest 
mean triglyceride rate was found in the DM group 
with CV complications, followed by DM without 
the complications of CV and the lowest in the non-
DM group (202.5 ± 178.9 vs 183.2 ± 34.9 vs. 104.6 
± 78.2 mg/dl). 
The mean of LDL cholesterol level was 
highest in the DM group without complications of 
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CV, followed by the non-DM group and the DM 
group with CV complications (115.2 ± 34.9 vs 
109.7 ± 30.2 and 105.7 ± 47.4 mg/dl). The highest 
HDL cholesterol average level was found in the 
non-DM group, followed by DM without CV 
complications and DM group with CV 
complications (42.4 ± 6.3 vs 37.6 ± 7.0 vs. 34.3 ± 
4.1mg / dl). 
 
 
Table 1. Description of the subject  
Parameter                                                Mean±SD 
                                                                Min-maks 
Control                      
(n=26) 
DM without CV 
(n=30) 
DM with CV 
(n=30) 
Age(years)                                               Mean±SD 
                                                           Min-maks 
32.7 ± 6,3 
22-51 
56.2 ± 9.7 
36-75 
59.3 ± 7.8 
40-73 
Sexuality (total/in %)                              Man 
                                                                Woman 
12 (46.2) 
14 (53.8) 
10 (33.3) 
20 (66.7) 
23 (76.7) 
7 (23.3) 
Smoking (total/in %)                               Yes 
                                                                 No 
7 (26.9) 
19 (73.1) 
6 (20.0) 
24 (80.1) 
19 (63.3) 
11 (36.7) 
BMI                                                         Mean±SD 
                                                           Min-maks 
23.3 ± 4.5 
17.6-39.8 
22.8 ± 2.5 
18.4-27.6 
25.6 ± 2.2 
22.4-29.8 
Long suffering  from                               Mean±SD 
DM(years)                                               Min-maks 
 6.9 ± 3.2 
3-15 
9.0 ± 3.5 
5-20 
Fasting blood glucose(mg/dl)                  Mean ±SD 
                                                                 Min-maks 
84.1 ± 9.1 
69-110 
167.7 ± 52.4 
100-285 
186.9 ± 90.0 
65-451 
2 hours  Post Prandial glucose                 Mean±SD 
(mg/dl)                                                     Min-maks 
89.4 ± 19.1 
57-152 
259.8 ± 69.3 
132-434 
258.2 ± 117.0 
118-605 
Total Cholesterol(mg/dl)                         Mean±SD 
                                                                 Min-mak 
183.2 ± 32.2 
145-298 
183.2 ± 34.9 
110-267 
165.0 ± 50.5 
110-267 
Triglyseride (mg/dl)                                 Mean±SD 
                                                            Min-maks 
104.6 ± 78.2 
47-451 
151.2 ± 78.4 
62-419 
202.5 ± 178.9 
62-419 
LDL (mg/dl)                                             Mean±SD 
                                                            Min-maks 
109.7 ± 30.2 
77-223 
115.2 ± 34.9 
49-207 
105.7 ± 47.4 
39-205 
HDL (mg/dl)                                            Mean±SD 
                                                            Min-maks 
42.4 ± 6.3 
35-63 
37.6 ± 7.0 
27-66 
34.3 ± 4.1 
24-45 
Homocysteine(µml/dl)                             Mean±SD 
                                                            Min-maks 
7.7 ± 1.7 
5.0-13.0 
13.1 ± 15.7 
4.0-93.9 
13.1 ± 3.7 
6.4-26 
Table 2 Differences in levels of homocysteine and lipid profiles between groups 
Group Hcy Cholesterol LDL-C HDL-C Triglyseride 
Non-DM and DM without CV complication 0.086    0.999  0.531         0.009*          0.030*  
         
Non-DM and DM wth CV complication 0.000*            0.111       
 
0.710          
 
0.000*           
           
0.013*                
DM without and with CV complication   0.993   0.111  0.383   0.033*     0.156 
 
 
 
Differences in levels of Homocysteine and 
Lipid Profiles between Groups 
Difference test for each variable between 
groups were done by using independent t test for 
Hcy level and lipid profile, and can be seen in 
Table 2. 
 
Homocysteine 
The results showed that there were 
significant difference on Hcy levels between non-
DM group and DM group with CV complications 
of (p=0.000). However, there was no significant 
difference between non-DM group and DM group 
without CV complication (p=0.086), as well as 
between DM group without and with CV 
complication (p=0.993). 
 
Lipid profile 
The results of data analysis in this study 
showed that there is no significant difference 
between total cholesterol and LDL cholesterol in 
the non-DM group and DM without CV 
Homocysteine and lipid on DM 
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complications (p=0.999 and p=0.531); non-DM 
and DM with CV complication (p=0.111 and 
p=0.710); DM without and with complications 
(p=0.111 and p=0.383)  
We found there were significant differences in 
HDL cholesterol levels between the non-DM 
group and the DM group without CV complication 
(p=0.009), between the non-DM group and the 
DM group with CV complications (p=0.000), as 
well asq between the DM group without and with 
CV complications (p=0.033). In this study there 
was a significant difference in triglyceride levels 
between the non-DM group and the DM group 
without CV complications P=0.030) and with CV 
complication (p = 0.013). There was no significant 
difference of triglyceride level between the DM 
group without and with CV complication 
(p=0.156) 
DISCUSSION 
 Obesity, DM, and duration of DM were 
the risk factors for cardiovascular disease, the 
mean duration of DM in this study was longer in 
the DM group with CV complications.  The mean 
fasting blood glucose level was higher in the 
group with CV complications (186.9 ± 90.0 mg/Dl) 
compared to group without CV complications 
(167.7 ± 52.4 mg/dl), but the mean 2 hours PP 
blood glucose levels of both two groups were 
similar. 
High triglyceride levels and low HDL levels 
are risk factors for cardiovascular disease. High 
Hcy levels are also risk factor for cardiovascular 
disease as found in the DM group with 
complications of CV. 
 
Homocysteine 
The majority of diabetes mellitus subjects 
with cardiovascular complication were: males 
(76.7%), the oldest age among the three groups, 
the highest fasting glucose level compared to the 
other two groups, smoking (63.3%), the highest 
BMI and longer suffering from DM (table 1). All 
of these factors are risk factors for cardiovascular 
disease. The risk factors of 
hyperhomocysteinemia encountered in this group 
are male, higher BMI, smoking and DM. As we 
know increasing levels of Hcy also a risk factor for 
cardiovascular disease. There was significant 
difference in Hcy levels between the non DM 
group and the DM with cardiovascular 
complication, eventhough still in the normal 
range. 
 Homocysteine is an amino acid which is a 
metabolic intermediate in the metabolism of 
essential amino acids methionine.6 Homocysteine 
is found in daily diets, and high levels are 
common in atherosclerotic DM and CHD. Thus, 
Hcy is strong independent predictors of CHD 
occurrence. Association between Hcy and 
atherosclerosis remains unclear, suspected to be 
associated with free radicals, smooth muscle cell 
stimulation and changes in platelets and 
hemostasis. Hyperhomocysteinemia is a risk 
factor for endothelial dysfunction.  Homocysteine 
levels are higher in patients DM and is a risk of 
CHD.(9) 
The results of various studies on the effect of 
glycemic control on plasma Hcy were 
inconsistent. Previous studies suggested that 
there was no correlation between Hcy and 
glycemic control. Hoogoven et al reported that 
there is no association between Hcy and HbA1c. 
Another study conducted by Aghamohammadi et 
al, examined the association between Hcy levels 
and glycemic control in 70 men with type 2 DM 
and concluded that there was no correlation 
between Hcy on glycemic control.(10)  Diabetes 
has a CVD risk of 2 to 4 times compared to non-
diabetes and atherosclerotic also develops despite 
mild glucose tolerance disorder.  
Homocysteine is an interesting topic in 
vascular disease in recent years, elevated Hcy 
levels can increase CVD and mortality in the 
population. Increased Hcy levels are also present 
in DM patients but their association with CVD 
remains unclear.  
Studies in humans showed that Hcy spurred 
atherosclerosis, it is characterized by platelet 
accumulation and thrombus formation in the 
endothelial area of the lesion. Hcy stimulates 
endothelial injury in sub-endothelial matrices 
that will stimulate platelet activation.(11) Other 
researchers pointed out that Hcy is a risk factor 
for type 2 DM not only for coronary events but 
also deaths from cardiovascular, retinopathy and 
microalbuminuria.(12) 
Several cross-sectional studies and case 
control studies showed that moderate HHcy 
increased risk factors for atherosclerosis and 
cardiovascular disease (CVD). Some researchers 
found significant Hcy effect on CVD. Recent 
studies mention that HHcy contribute 10% to the 
risk of Coronary artery diseases (CAD). Although 
possible mechanism explaining the relationship 
of plasma homocysteine level and CVD is 
inconclusive. The most possible hypothesis that 
elevated homocysteine levels is endothelium 
dysfunction due to enhanced oxidative stress and 
reduced the production and bioavailability of 
nitric oxide (a strong relaxing factor) of the 
endothelium .(13) 
 
Lipid Profile 
Abnormal lipids are often primarily found in 
DM type 2. The prevalence of dyslipidemia in DM 
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is 95%. Dyslipidemia is a major risk factor for 
CHD which is a cause of morbidity and mortality 
in DM patients due to elevated serum 
triglycerides (69%), cholesterol (56%), LDL-C 
(77%) and HDL-C decrease (71%). Hyperlipidemia 
is the most common complication of DM and 
predisposes to atherosclerosis and macrovascular 
complications. The most common abnormal lipids 
in DM are elevated triglycerides, LDL-C and 
decreased HDL-C. Good glycemic control will 
prevent the development and progression of 
abnormal lipids in DM patients.(14) 
Several factors can affect lipid levels in 
patients with DM, such as interrelation between 
carbohydrates (CH) and lipid metabolism. 
Therefore, any interference on CH metabolism 
will cause disruption of lipid metabolism and vice 
versa. Insulin resistance is a primary defect in 
majority of DM type 2 and in non-DM insulin 
resistance and hyperinsulinism is a predictor 
factor of progression to DM type 2. Some studies 
indicate that insulin affects apolipoprotein 
production by the liver, regulates activity of 
enzyme lipoprotein lipase and cholesterol ester 
transfer protein (CETP) causing dyslipidemia in 
DM. In addition, insulin deficiency decreases 
hepatic lipase activity and some of the production 
stages of biologically active lipase protein.(15) 
This study obtained no significant difference 
on Total Cholesterol and LDL-C between each 
group,  this is probably due in DM patients with 
CV complications has been aware to keep his diet 
and is probably already taking oral diabetic 
medications and anti-lipidemia, despite trying 
dug this questioners. It is evidenced by mean 
cholesterol and LDL-C levels were higher in the 
DM group without CV complications compared 
with DM group with CV complication. 
Pakard et al reported a decrease in HDL-C is 
a strong predictor of CHD, while Goldberg 
reported hyperglycemia progressive increase 
transfer of cholesterol esters from HDL-C to 
particles VLDL-C, then the LDL-C particle solids 
will acquire the majority of HDL ester and will 
reduce levels of HDL-C. Improved glycemic 
control will increase HDL-C, poor glycemic 
control will lower lipoprotein levels. Poor 
insulinization will increase lipolysis in adipose 
tissue which will increase fatty acid (FA) 
transport to the liver and increase VLDL-C. 
Insulin directly degrades Apo B (the main protein 
VLDL-C) and increases Apo B secretion.(15) 
The highest level of HDL-C was found in Non 
DM group, followed by DM group without CV 
complication and the lowest in DM group with CV 
complication. 
Decreased HDL-C levels are associated with 
an increased risk of CHD. HDL-C is cardio-
protective. Decreased HDL-C is often 
accompanied by increased levels of 
trigliceride.(16) HDL-C decreases in DM due to 
decreased lipoprotein activity because the rate of 
HDL2 formation depends on the flux rate of the 
surface component of triglyceride rich lipoprotein 
mediated in part by lipoprotein lipase. When 
VLDL-C mediated by LPL catabolism is efficient, 
the availability of surface components for HDL-C 
transfer is increased, when undisturbed VLDL-C 
lipolysis will result in a decrease in HDL-C. 
Increased HDL-C catabolism due to   
hypertriglyceridemia, triglyceride transfer rate to 
HDL2 high and will result in triglyceride-rich 
HDL2 susceptible to catabolism by hepatic 
triglyceride lipase. Increased activity of 
cholesterol - ester transfer proteins (CETP), 
which modify pathological lipid composition of the 
sub-population of apoprotein B containing 
lipoproteins to form atherogenic b-like VLDL 
particles, so the increased activity of CETP are 
atherogenik.(3) Descriptive data in this study 
showed that the lowest average of fasting glucose 
level in the non-DM group and the highest in the 
DM group with CV complications, the same case 
was found in the triglyceride level, the highest 
level was found in the DM group with CV 
complications (Table 1). 
Dyslipidemia increased in patients with 
elevated blood glucose levels. 
Hypertriglyceridemia is the most common lipid 
abnormality found in type 2 diabetes mellitus 
(73.3%)(15)(12)Other researchers attributed high 
triglyceride levels to poor glycemic control in 
patients with diabetes mellitus and obesity, 
thought to be associated with decreased 
lipoprotein lipase activity in muscle and adipose 
tissue.(15) 
DMT2 is associated with elevated triglyceride 
and VLDL-C levels due to elevated glucose and 
FFA, VLDL-C and triglyceride clearance 
disorders resulting from decreased lipase activity 
of lipase proteins especially in moderate-severe 
hypertriglyceridemia indicating both deficiency 
and insulin resistance. In diabetes due to 
hypertriglyceridemia, large particles of 
triglyceride rich VLDL are secreted. Changes in 
VLDL composition have implications for 
increasing the propensity for atherosclerosis.(17) 
Evidence of the relationship between plasma 
triglyceride levels and the risk of coronary 
arterial disease (CAD) is broadly based on 
epidemiological studies. Meta-analysis of 7 
populations based on prospective studies found 
that each 1 mmol/ L increase in triglyceride levels 
increased the risk of 32% of coronary disease in 
men and 76% in women after corrected with HDL-
C effects to 14% in men and 37% in women. The 
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direct atherogenic effects of triglyceride rich 
particle especially IDL-C and the remnant 
lipoprotein may independently contribute to 
plasma triglyceride levels as cardiovascular risk 
factors. It is said that dyslipidemia is associated 
with insulin resistance in DMT2 and is strongly 
associated with increased cardiovascular risk.(13) 
 
CONCLUSION 
The highest Hcy level, the lowest HDLC and 
the highest Triglyceride level found on DM with 
CV complication. 
 
ACKNOWLEDGMENT 
The authors acknowledge the technical 
contributions of Dr.Angeline Barbara Mailoa, Dr  
Prihartiwi Purnamasari from Clinical 
Pathology Department Faculty of Medicine 
Diponegoro University for sampling assistant, as 
well as Farida Martyaningsih from Central 
Laboratory Faculty of Medicine Diponegoro 
University for laboratory assistant. This work 
was supported in part by Faculty of Medicine 
Diponegoro University. 
 
No potential conflicts of interest relevant to 
this article were reported. 
 
REFERENCES 
1.  Tagoe DNA, Amo-Kodieh P. Type 2 Diabetes 
Mellitus Influences Lipid Profile of Diabetic 
Patients. Ann Biol Res. 2013;4(6):8–92.  
2.  Victor A. Retinopati Diabetik Penyebab 
Kebutaan Utama Penderita Diabetes Rumah 
Diabetes Informasi dan Panduan Lengkap 
Diabetes. 2008;  
3.  Perkumpulan Endokrinologi Indonesia. 
Konsesus Pengendalian Dan Pencegahan 
Diabetes Mellitus Tipe 2 Di Indonesia. 
Perkeni. 2011;  
4.  Naseb NM, Peela JR, Shakila S, Said AR, 
Peela LT, Yedla RN. Homocysteine, an early 
predictor of cardiovascular risk in type2 
diabetes mellitus. Clin Chem Lab Med 
[Internet]. 2014;52(June):S560. Available 
from: 
http://www.embase.com/search/results?subac
tion=viewrecord&from=export&id=L7155593
3%5Cnhttp://dx.doi.org/10.1515/cclm-2014-
4014%5Cnhttp://rug.on.worldcat.org/atoztitle
s/link/?sid=EMBASE&issn=14346621&id=do
i:10.1515%2Fcclm-2014-
4014&atitle=Homocysteine%2C+an+earl 
5.  Hankey G., Eikelboom JW, Ho W., Bockxmeer 
F. Clinical Usefulness of Plasma 
Homocysteine in Vascular Disease. Med J 
Aust. 2004;181(6):314–8.  
6.  Brazionis, Harper C., Rowley K., ’Dea K., 
Tsopoulus C. Homocysteine and Diabetic 
Retinopathy. Diabetes Care. 2008;31(1):0–6.  
7.  Jayakrishnan S, Vidya V, Jayanthii BA.-N. 
Cardiacc Biomarker, Lipids and Homoysteine 
In Type 2 Diabetes Mellitus with and without 
Complication. Gjra-Global J Res Anal. 
2015;4(9).  
8.  Heydari-Zaingh H, Nejal-Shookohi A, 
Nourozi A. Effect of Glycaemic Control On 
Homocysteine Levels in Type 2 Diabetic 
Patients with and without Cardiovascular 
Disease. Zahedan J Res Med Sci. 
2014;16(1):23–7.  
9.  Rudy A, Kowalska I, Straczkowski M, 
Kinalska I. Homocysteine Concentration and 
Vascular Complications in Patients with Type 
2 Diabetes. Diabetes Metab. 2005;31:112–7.  
10.  Zarnagh H., Shookohi A., Nourozi A. Effect of 
Glycemic Control on Homocysteine Levels in 
Type 2 Diabetic Patients Without 
Cardiovascular Disease. Zahedan J Res Med 
Sci. 2014;16(1):23–7.  
11.  Welch G, Localso J. Homocysteine and 
Atherothrombosis. N Engl J Med. 
1998;338(15):1042–52.  
12.  Sangma M, Devi KG, Florence L, Singh A, 
Jamir S, Roel S, et al. Serum Homocysteine 
and Lipid Profile in Type 2 Diabetes Mellitus 
Patients. IOSR-JDMS. 2015;14(1):76–9.  
13.  Mishra N. Hyperhomocysteinemia: A Risk of 
CVD. Int J Res Biol Sci. 2016;6(1):13–9.  
14.  Uttra K., Devrajani B., Shah, S, Z A, 
Devrajani T, Das T, Raza S, et al. Lipid Profile 
of Patients with Diabetes Mellitus (A 
Multidiciplinary Study). World Appl Sci J. 
2011;12(9):1382–4.  
15.  Dixit A., Dey R, Suresh A, Chauduri S, Panda 
A., Mitra A, et al. The Prevalence of 
Dyslipidemia in Patients With Diabetes 
Mellitus of Ayurveda Hospital. J Diabetes 
Metab Disord. 2014;13:58.  
16.  Krauss M. Lipid and Lipoproteins in Patients 
with Type 2 Diabetes. Diabetes Care. 
2004;27:1496–504.  
17.  Prasannakumar K. Pathogenesis of 
Dyslipidaemia in Diabetes. 2016;  
B. Rachmawati et al 
